IGF-1 DES 1,3 1mg

IGF-1 DES 1,3 is a synthetic peptide of insulin-like growth factor 1 (IGF-1) made through recombinant synthesis. IGF-1 DES 1,3 lacks 3 amino acids from the N-terminus of the peptide (Gly-Pro-Glu). This creates a peptide consisting of only 67 amino acids, compared to the 70 amino acids of IGF-1. IGF-1 DES 1,3 is also a naturally-occurring splice variant found in the human brain and animal models¹ The shortened peptide variant has the additional benefit of being 10 times more potent than endogenous IGF-1. This is because IGF-1 DES 1,3 does not bind as effectively to insulin-like growth factor-binding proteins (IGFBPs), which significantly enhances its bioavailability. This trait makes IGF-1 DES 1,3 a desirable peptide to use in in vitro and in vivo studies for addressing conditions involving IGF-1. IGF-1 DES 1,3 has been studied in many different settings, including investing its effects in neurological disorders, as well as modulating the immune system. IGF-1 has long been known to play a role in neuronal health and survival, particularly in maintaining mature synapses. Researchers hypothesize that analogs of IGF-1 may be beneficial in improving autism deficits, in addition to improving cognition and memory in aging people.^2,3,4 IGF-1 DES 1,3 can also improve immune system function by enhancing mononuclear cell and neutrophil function.⁵ The peptide may promote wound and skin healing as well by bypassing inflammatory pathways that interfere with normal IGF-1 function. Since IGF-1 DES 1,3 does not bind well to IGFBPs, it is available in inflammatory environments to stimulate fibroblast growth, leading to accelerated wound healing.⁶  

IGF-1 DES 1,3 is available as a white lyophilized powder at a concentration of 1 mg/vial. This product is intended for laboratory research purposes only.

References: 1. Ballard FJ, WAllace JC, Francis GL, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-7. 2. Steinmetz AB, Stern SA, Kohtz AS, et al. Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice. J Neurosci. 2018;38(4):1015-1029. 3. Ramsey MM, Adams MM, Ariwodola OJ, et al. Functional characterization of des-IGF-1 action in excitatory synapses in the CA1 region of rat hippocampus. J Neurophysiol. 2005;94(1):247-54. 4. Gorecki DC, Beresewicz M, Zablocka B. Neuroprotective effects of short peptides derived from the Insulin-like growth factor 1. Neurochem Int. 2007;51(8):451-8. 5. Zhao X, McBride BW, Trouten-Radford LM, Burton JH. Effects of insulin-like growth factor-I and its analogues on bovine hydrogen peroxide release by neutrophils and blastogenesis by mononuclear cells. J Endocrinol. 1993;139(2):259-65. 6. Yateman ME, Claffey DC, Hughes SCC, et al. Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production. J Endocrinol. 1993;137(1):151-9.